Fight against Ebola
PURE Bioscience, Inc. (OTCQB: PURE) Has Joined Other Top Ebola Stock Movers
With the first recorded ebola death reaching U.S. soil, citizens are becoming more concerned about this deadly disease. As always, investors have looked for stock opportunities to arise from increased media attention. Several companies have seen excellent price action stemming from their health sector involvement and potential ebola treatment participation. Companies like Sanomedica International Hondings, Inc. (OTCQB: SIMH), Lakeland Industries, Inc. (NASDAQ: LAKE), Revolutions Medical Corp. (OTCPK: RMCP), and iBio, Inc. (NYSE: IBIO) have all seen powerful bullish price movement in recent days.
PURE's hard surface disinfectant and food contact surface sanitizer product kills bacteria in just 30 seconds. This is a powerful disinfectant, which can be used to kill pathogens like MRSA, fungi, and even some viruses like HIV, Norovirus, Influenza A, Avian Influenza, and H1N1. Updates on the effects of the disinfectant on the ebola virus have not yet been released. Investors are still waiting for this information. With the recent speculation in the bioscience industry, PURE has developed a great deal of attention from traders, seeing share prices surging as high as $1.20. Accumulation has surged on the speculation, and volume has reached record levels. Additionally, the company just released an update promising to reduce pathogens on leafy greens. The company has released exciting updates to shareholders, which is helping to catalyze this price action. EPA-registered PURE™
Hard Surface disinfectant and food contact surface sanitizer provides an unparalleled combination of high efficacy and low toxicity with 30-second bacterial kill times and 24-hour residual protection. PURE Hard Surface completely kills resistant pathogens like MRSA and also effectively eliminates dangerous fungi and viruses including HIV, Norovirus, Influenza A, Avian Influenza and H1N1. PURE Hard Surface is registered for use on food contact surfaces and is gentle enough to be used in childcare environments.
SDC is non-toxic, non-caustic, colorless, odorless, tasteless and does not produce toxic fumes. While SDC is highly toxic to bacteria, fungus and virus it is non-toxic to humans and animals. Based on the EPA toxicity categorization of antimicrobial products that ranges from Category I (high toxicity) down to Category IV, at use dilutions, SDC is rated in the lowest toxicity category, IV, while traditional disinfectants fall into Categories I and II.
SDC-Based Hard Surface Disinfectant
SDC is the basis for the EPA registered hard surface disinfectant, PURE Hard Surface. Twenty times faster than the leading disinfectants, PURE Hard Surface is the next generation of microbial control. Advantages of SDC include:
- Powerful broad spectrum protection as a disinfectant, fungicide and virucide
Kills germs in 30 seconds
Provides residual protection for 24 hours
Effective against resistant bacteria such as MRSA and VRE
Lowest toxicity rating available
Labeled for use in diverse environments including restaurants, homes, medical facilities, institutions, day care facilities and on children's toys and play areas
PURE Hard Surface Efficacy
SDC as an Additive or Active Ingredient
PURE produces and markets varying strengths of SDC concentrate for use as an additive or active ingredient in other products. PURE pursues strategic development, licensing and distribution agreements with partner companies for the third party products containing SDC as an additive or active ingredient.
SDC for Personal Care
SILVÉRION 2400 Technical Data Sheet
For Samples or to Purchase of SILVÉRION 2400 for personal care use, click here
FDA Regulated SDC-Based Product Development
PURE's SDC technology also shows promise as a broad-spectrum antimicrobial and anti-fungal for use in human and veterinary healthcare products. PURE has initially chosen to pursue approvals through the U.S. Food and Drug Administration (FDA) by partnering with third-party pharmaceutical development companies. Our partner companies assume responsibility for finding and managing the testing and regulatory process for potential FDA regulated SDC-based products. Current product development projects include dermatology, wound care and medical biofilm control products as well as several products for dental industry. An IND for a hand sanitizer is in process.